DERMATOLOGIE PRO PRAXI / Dermatol. praxi. 2025;19(2):75-80 / www.dermatologiepropraxi.cz 80 SDĚLENÍ Z PRAXE Děti předškolního věku úspěšně léčené dupilumabem LITERATURA 1. Bhatt M, Lal K, Silverberg NB. Special Considerations in Atopic Dermatitis in Young Children. Dermatol Clin. 2024 Oct;42(4):611-617. doi: 10.1016/j.det.2024.05.003. Epub 2024 Jul 9. PMID: 39278714. 2. Wang SP, Stefanovic N, Orfali RL, et al. Impact of climate change on atopic dermatitis: A review by the International Eczema Council. Allergy. 2024 Jun;79(6):1455-1469. doi: 10.1111/ all.16007. Epub 2024 Jan 24. PMID: 38265114. 3. Gu C, Yao X, Li W. Burden of Disease; the Current Status of the Diagnosis and Management of Atopic Dermatitis in China. J. Clin. Med. 2023;12:5370. https://doi.org/10.3390/ jcm12165370. 4. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo- -controlled, phase 3 trial. Lancet. 2022 Sep 17;400(10356):908919. doi: 10.1016/S0140-6736(22)01539-2. PMID: 36116481. 5. Kruse LL, Mancini AJ. Atopic Dermatitis in Children. Pediatr Ann. 2024 Apr;53(4):e121-e128. doi: 10.3928/1938235920240205-02. Epub 2024 Apr 1. PMID: 38574071. 6. Paller AS, Pinter A, Wine Lee L, et al. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis. Adv Ther. 2024 Mar;41(3):1046-1061. doi: 10.1007/ s12325-023-02753-1. Epub 2024 Jan 9. Erratum in: Adv Ther. 2024 Jun;41(6):2536-2539. doi: 10.1007/s12325-024-02866-1. PMID: 38194047; PMCID: PMC10879230. 7. Mehta Y, Fulmali DG. Relationship Between Atopic Dermatitis and Food Allergy in Children. Cureus. 2022 Dec 31;14(12):e33160. doi: 10.7759/cureus.33160. PMID: 36726939; PMCID: PMC9886409. 8. Song K, Zhang Y, Wang L, et al. Risk Factors of Onset Time and Persistence of Atopic Dermatitis in Children Under Age 5 Years: A Cross-Sectional Study. Dermatitis. 2024 Jan- -Feb;35(S1):S47-S54. doi: 10.1089/derm.2023.0125. Epub 2023 Dec 22. PMID: 38133542. 9. Yu X, Li L. A Multi-centre Analysis of Serum IgE Levels in Atopic Dermatitis. Indian J Dermatol. 2024 Nov-Dec;69(6):486. doi: 10.4103/ijd.ijd_151_24. Epub 2024 Oct 29. PMID: 39678742; PMCID: PMC11642463. 10. Lee S, Fun Jae K, Aigbekaen I, et al. Investigating the Use of Melatonin in Children with Atopic Dermatitis: A Cross-sectional study. Poster presented at the 83rd Annual Meeting of the American Academy of Dermatology (AAD); Orlando, FL, USA; March 7.–11. 2025. 11. Kimland EE, Dahlén E, Martikainen J, et al. Melatonin Prescription in Children and Adolescents in Relation to Body Weight and Age. Pharmaceuticals (Basel). 2023 Mar 6;16(3):396. doi: 10.3390/ph16030396. PMID: 36986495; PMCID: PMC10058986. 12. Bruni O, Breda M, Nobili L, et al. European expert guidance on management of sleep onset insomnia and melatonin use in typically developing children. Eur J Pediatr. 2024 Jul;183(7):2955-2964. doi: 10.1007/s00431-024-05556-w. Epub 2024 Apr 16. PMID: 38625388; PMCID: PMC11192690. 13. Paller AS, Siegfried EC, Cork MJ, et al. Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2024 Mar;26(2):163-173. doi: 10.1007/s40272-023-00611-9. Epub 2024 Jan 24. PMID: 38267692; PMCID: PMC10890978. 14. Wollenberg A, Werfel T, Ring J, et alAtopic Dermatitis in Children and Adults – Diagnosis and Treatment. Dtsch Arztebl Int. 2023 Mar 31;120(13):224-234. doi: 10.3238/arztebl. m2023.0011. PMID: 36747484; PMCID: PMC10277810. 15. Carrascosa JM, Morillas-Lahuerta V. Comorbidities in Atopic Dermatitis: An Update and Review of Controversies. Actas Dermosifiliogr (Engl Ed). 2020 Jul-Aug;111(6):481-486. English, Spanish. doi: 10.1016/j.ad.2020.04.009. Epub 2020 May 13. PMID: 32401719. 16. Gilaberte Y, Pérez-Gilaberte JB, Poblador-Plou B, et al. Prevalence and Comorbidity of Atopic Dermatitis in Children: A Large-Scale Population Study Based on Real-World Data. J. Clin. Med. 2020;9:1632. https://doi.org/10.3390/jcm9061632. 17. DUPIXENT® EU SmPC. Available from: https://www.ema. europa.eu/cs/documents/product-information/dupixent-epar-product-information_cs.pdf. 18. Lieberman JA, Chu DK, Ahmed T, et al. A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 2024 Sep;133(3):286294. doi: 10.1016/j.anai.2024.05.014. Epub 2024 Jun 5. Erratum in: Ann Allergy Asthma Immunol. 2025 Feb;134(2):242243. doi: 10.1016/j.anai.2024.10.023. PMID: 38848870; PMCID: PMC11459655. 19. Amy S, Paller EL, Simpson EC, et al. Dupilumab Safety and Efficacy up to 3 Years in Children Aged 6 Months to 11 Years With Atopic Dermatitis. Poster presented at the 83rd Annual Meeting of the American Academy of Dermatology (AAD); Orlando, FL, USA; March 7.–11., 2025. 20. Beck AL, Paller AS, Siegfried EC, et al. Dupilumab Treatment Significantly Reduces Age-Dependent Total IgE Levels in Young Children With Atopic Dermatitis. Poster presented at the 83rd Annual Meeting of the American Academy of Dermatology (AAD); Orlando, FL, USA; March 7.–11. 2025. 21. Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024 Jul;25(4):655-668. doi: 10.1007/s40257-024-00859-y. Epub 2024 May 14. PMID: 38743155; PMCID: PMC11193700. … nenechte si ujít aktuální informace o možnostech medicínského vzdělávání FACEBOOK https://www.facebook.com/ SolenMedicalEducation/ @SolenMedicalEducation LINKEDIN https://www.linkedin.com/ company/solen-medical-education/ #solenmedicaleducation X https://twitter.com/ MedicalSolen @MedicalSolen ODEMČENÉ AKTUÁLNÍ ČLÁNKY PŘEHLED O VZDĚLÁVACÍCH AKCÍCH UPOZORNĚNÍ NA ZVÝHODNĚNÉ CENY SOUTĚŽE O VSTUPENKY NA KONGRESY INFORMACE O ON LINE KURZECH NOVINKY V E SHOPU … a mnoho dalšího
RkJQdWJsaXNoZXIy NDA4Mjc=